Press Releases

Presentation During New Advances in the Management of Pancreatic Cancer Course Highlights Intra-Arterial Chemotherapy as a Potential Innovative Treatment for Pancreatic Cancer

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its novel therapy platform, RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion), will be highlighted during a presentation by expert panelist, Dr. Ripal Gandhi, at the Miami Cancer Institute’s New…
Read More

RenovoRx Announces Pricing of Initial Public Offering

RenovoRx, Inc., a biopharmaceutical company and innovator in targeted cancer therapy, today announced the pricing of its underwritten initial public offering of 1,850,000 units at a public offering price per unit of $9.00.  Each unit consists of one share of…
Read More

RenovoRx Announces Issuance of Seventh U.S. Patent

RenovoRx, a biopharmaceutical company and innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office issued U.S. Patent No. 11,052,224. This new patent extends the Company’s extensive coverage of its novel RenovoRx therapeutic Trans-Arterial Micro-Perfusion (RenovoTAMP™)…
Read More

RenovoRx Named 2020 Winner in the Fierce Innovation Awards for Life Sciences

RenovoRx, an innovator in targeted cancer therapy, today announced it won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020. The peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma honors companies demonstrating innovative solutions, technologies, and services that could make the…
Read More

RenovoRx Announces Sixth U.S. Patent

RenovoRx, an innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office has allowed U.S. Patent Application number 15,807,011. This new patent will broadly cover RenovoRx’s unique therapeutic method called Trans-Arterial Micro-Perfusion (TAMPTM) which is designed…
Read More

RenovoRx Announces Issuance of Fifth U.S. Patent

RenovoRx, an innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office issued U.S. Patent 10,512,761 covering kits for delivery of chemotherapeutic agents within the body. These kits may be used for the localized and specific…
Read More

Contemporary Management of Pancreatic Cancer

An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies. Reviews how recent advances in surgery, radiation therapy, ablative options, and endovascular therapies have brought promise and hope to patients with…
Read More

RenovoRx Announces FDA Clearance for Expanded Labeling

RenovoRx, manufacturer of the RenovoCath adjustable dual-balloon infusion catheter, today, announced it has received FDA 510(k) clearance to expand its indications for use to include the ‘delivery of chemotherapeutics’. The RenovoCath device isolates segments of the peripheral vasculature, allowing physicians…
Read More

Presentation of Tumor Cases Treated with Embolotherapy

Dr. David Madoff of NewYork-Presbyterian Hospital Weill Cornell Medical Center presented on his experience using novel technologies and techniques in difficult to treat tumor cases at the AIM/VEITH Symposium, November 14, 2016. In his presentation Dr. Madoff discussed advancements in…
Read More

RenovoRx Begins Post-market Registry Study

RenovoRx has announced the opening of its post-market registry study, which will assess patient survival and clinical outcomes of the RenovoCath catheter when used to deliver gemcitabine and other chemotherapeutic agents to pancreatic tumors. The study will include up to…
Read More

RenovoRx Joins Stanford-Backed StartX Med Program

RenovoRx, a leading developer of innovative solutions for targeted delivery of therapeutics to selected sites in the peripheral vascular system, today announced that the company was selected by the Stanford-affiliated StartX MED program for its Fall 2015 session. StartX is…
Read More

RenovoRx Receives CE Mark for RenovoCath™

RenovoRx, a leading developer of innovative solutions for targeted delivery of fluids to selected sites in the peripheral vascular system, today announced that the company achieved the CE Mark for commercial sale of the RenovoCath™. The catheter will offer EU…
Read More

First Patient Enrolled in Study Using the RenovoCath ™

El Camino Hospital in Mountain View, California has enrolled the first patient in a safety study using the RenovoCath™, a new catheter that is being introduced for targeted delivery of fluids to selected sites in the peripheral vascular system. The…
Read More

First In-Human Use of RenovoCath™ Catheter

RenovoRx today announced the first in-human use of the RenovoCath™ catheter. RenovoRx is a leading developer of innovative solutions for targeted delivery of fluids, including therapeutic agents, to selected sites in the vascular system The patient underwent localized large vein…
Read More

RenovoRx Achieves ISO 13485 Certification

RenovoRx, a leading developer of innovative solutions for targeted delivery of fluids to selected sites in the vascular system,today announced that it has achieved ISO 13485:2003 certification, an internationally recognized quality standard for medical devices. BSI (the British Standards Institution)…
Read More

RenovoCath™ RC120 Receives FDA 510(k) Clearance

RenovoRx, a leading developer of innovative solutions for targeted delivery of fluids to selected sites in the vascular system, today announced the company has received FDA 510(k) clearance of its flagship product, the RenovoCath RC120 catheter.
Read More

RenovoRx Patent Issued

RenovoRx, a leading developer of innovative solutions for the isolation of blood flow and delivery of fluids to selected sites in the vascular system, today announced that the United States Patent and Trademark Office has issued U.S. patent application number…
Read More
Injection directly into tumor ball

RenovoRx Named TiE50 2013 Winner

RenovoRx today announces that it has been chosen as a winner of the 2013 TiE50 Awards, a highly influential list of the most enterprising startup companies across five verticals: Internet, Software, Mobile, Life Sciences, and Energy.
Read More
Injection directly into tumor ball

RenovoRx Featured by START-UP

RenovoRx is featured in the February 2013 issue of START-UP, an Elsevier Business Intelligence publication of in-depth profiles of leading-edge companies and technologies.
Read More

* Individual results may vary.

Menu